Reyvow and Ajovy approved in China.

According to news from Lilly, Lilly's products Rinvoq and Taltz have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's disease and moderate to severe active ulcerative colitis in adults. Rinvoq and Taltz are IgG4 monoclonal antibodies that target the p19 subunit of interleukin-23, selectively inhibiting the IL-23 pathway and modulating the immune inflammatory response driven by it.